Table 3.

Molecular determinants for clinical response to ibrutinib

BCR pathway mutations
IDDiseaseBest responseCOOMYD88CD79BCARD11TNFAIP3
#12PCNSLCRNGCL265PWTWTWT
#4PCNSLCRNGCL265PWTWTWT
#17PCNSLCRNGCWTWTWTWT
#1PCNSLCRn/an/a
#6PCNSLCRn/an/a
#10PCNSLPRNGCL265PY196HWTWT
#11PCNSLPRGCBL265PY196DWTL324Qfs*7
#20PCNSLPRNGCL265PY196DWTDEL
#16PCNSLPRNGCV217FA43V/M164IR337QWT
#3PCNSLPRNGCM232TY196CS622delDEL
#19PCNSLSDNGCL265PY196SWTWT
#5PCNSLPDNGCWTWTR179QWT
#7PCNSLNGCWTWTWTWT
  • Abbreviations: COO, cell-of-origin (as determined by immunohistochemistry); n/a, not assessed due to lack of tissue; WT, wild-type; DEL, deletion; NGC, non-germinal center subtype; SD, stable disease; PD, progressive disease; —, not assessable.